Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Are computational complexity principles relevant for explaining brain activity?
Cristopher Moore discusses the nature of computation and whether we should think of neural activity as computing.
Are computational complexity principles relevant for explaining brain activity?
Cristopher Moore discusses the nature of computation and whether we should think of neural activity as computing.
This paper changed my life: Learning the molecular rules of cell identity
A 1987 Cell paper showed that a single transcription factor could turn fibroblasts into muscle cells. The work inspired Ardem Patapoutian to think about the molecular codes that define neuronal subtypes.
This paper changed my life: Learning the molecular rules of cell identity
A 1987 Cell paper showed that a single transcription factor could turn fibroblasts into muscle cells. The work inspired Ardem Patapoutian to think about the molecular codes that define neuronal subtypes.
Leucovorin saga, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 15 June.
Leucovorin saga, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 15 June.